MDNA Life Sciences acquires Mitomic Technology and product pipeline.
Continue reading “MDNA Life Sciences acquires Mitomic Technology”
Category: In the news
New prostate cancer tests could reduce false alarms
Sophisticated new prostate cancer tests are coming to market that might supplement the unreliable P.S.A. test, potentially saving tens of thousands of men each year from unnecessary biopsies, operations and radiation treatments.
Read the full article on the New York Times.
Mitomics: the next generation of molecular testing
In the world of early disease detection, Mitomics Inc. is pioneering the next generation of molecular testing. The Thunder Bay-based company is charting new territory with an innovative approach to the screening and diagnosis of cancer by using mitochondrial DNA (mtDNA) based biomarkers instead of traditional nuclear DNA-based biomarkers.
Read the full article on the Biotechnolgy Focus website.
Mitomics CSO Ryan Parr publishes data on mtDNA analysis used to re-identify Titantic’s unknown child
Titanic’s unknown child: The critical role of the mitochondrial DNA coding region in a re-identification effort.
Read the full report on the ScienceDirect website.
ARUP to offer Decode’s prostate cancer risk test, but Mitomics catching up
ARUP Labs plans to begin offering Decode’s prostate cancer-risk test to clients nationwide in the fall, the companies said.
Continue reading “ARUP to offer Decode’s prostate cancer risk test, but Mitomics catching up”